1. Reduction of APOE accounts for neurobehavioral deficits in fetal alcohol spectrum disorders.
- Author
-
Hwang, Hye, Yamashita, Satoshi, Matsumoto, Yu, Ito, Mariko, Edwards, Alex, Sasaki, Junko, Dutta, Dipankar, Mohammad, Shahid, Yamashita, Chiho, Wetherill, Leah, Schwantes-An, Tae-Hwi, Abreu, Marco, Mahnke, Amanda, Mattson, Sarah, Foroud, Tatiana, Miranda, Rajesh, Chambers, Christina, Torii, Masaaki, and Hashimoto-Torii, Kazue
- Subjects
Fetal Alcohol Spectrum Disorders ,Animals ,Mice ,Female ,Humans ,Pregnancy ,Apolipoproteins E ,Prenatal Exposure Delayed Effects ,Male ,Brain ,Genome-Wide Association Study ,Polymorphism ,Single Nucleotide ,Disease Models ,Animal ,Child ,Mice ,Inbred C57BL ,Ethanol - Abstract
A hallmark of fetal alcohol spectrum disorders (FASD) is neurobehavioral deficits that still do not have effective treatment. Here, we present that reduction of Apolipoprotein E (APOE) is critically involved in neurobehavioral deficits in FASD. We show that prenatal alcohol exposure (PAE) changes chromatin accessibility of Apoe locus, and causes reduction of APOE levels in both the brain and peripheral blood in postnatal mice. Of note, postnatal administration of an APOE receptor agonist (APOE-RA) mitigates motor learning deficits and anxiety in those mice. Several molecular and electrophysiological properties essential for learning, which are altered by PAE, are restored by APOE-RA. Our human genome-wide association study further reveals that the interaction of PAE and a single nucleotide polymorphism in the APOE enhancer which chromatin is closed by PAE in mice is associated with lower scores in the delayed matching-to-sample task in children. APOE in the plasma is also reduced in PAE children, and the reduced level is associated with their lower cognitive performance. These findings suggest that controlling the APOE level can serve as an effective treatment for neurobehavioral deficits in FASD.
- Published
- 2024